Cervical cancer continues to represent an immense burden worldwide. Fortunately, in all stages of the disease and therapeutic modalities there have been significant advances in the past 5 years with the promise of improving oncologic outcomes and decreasing morbidity. The introduction of immunotherapy into the care of patients with metastatic and recurrent cervical cancer, a disease with a historically poor prognosis and limited treatment options, has altered the standard of care.
No takes yet. Share an insight, caveat, or question.
Foley et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: